EANS-News: DEWB Investment Holding NOXXON Pharma AG Achieves Milestone in Partnership with Eli Lilly and Company

--------------------------------------------------------------------------------
Corporate news transmitted by euro adhoc. The issuer/originator is solely
responsible for the content of this announcement.
--------------------------------------------------------------------------------

Company Information

Jena/Berlin, Germany, December 3, 2009 (euro adhoc) - NOXXON Pharma
AG (NOXXON), the biopharmaceutical company focusing on the
development of novel medicines based on its unique proprietary
Spiegelmer® technology, announced today the achievement of an
important milestone in its drug discovery and development partnership
with Eli Lilly and Company (NYSE:LLY). NOXXON´s successful
identification of a Spiegelmer® with picomolar affinity and high
selectivity for its target met contractually specified milestone
criteria and triggers a payment of an undisclosed amount. Lilly and
NOXXON entered into the agreement last year to discover and develop
Spiegelmers® for the treatment of migraine.

NOXXON´s Chief Scientific Officer, Dr. Sven Klussmann, commented:
"The rapid delivery of what appears to be an immensely potent
compound illustrates the power of the Spiegelmer® platform and
represents the first major landmark in our partnership. We now look
forward to Lilly applying its substantial expertise in the field of
migraine in taking the Spiegelmer® to the next level."

William Chin, M.D., vice president of discovery and clinical research
at Lilly, added: "NOXXON´s identification of the lead compound is an
outstanding milestone achievement. The use of Spiegelmers® for the
potential treatment of migraine headache is a novel and promising
approach. We are excited to continue our work with NOXXON to bring
Spiegelmers® to our patients as soon as possible." Following the
completion of the discovery work, the identified Spiegelmer® will
undergo pharmacological testing and pre-clinical development. Lilly
is responsible for the pre-clinical and clinical development as well
as the commercialization of the Spiegelmer® product, provided the
product is approved by regulatory authorities.

About Spiegelmers® Spiegelmers® (L-aptamers) are chemical entities
based on synthetic mirror-image oligonucleotides which are highly
selective for their pharmacological target and potent inhibitors of
target function. They combine the benefits of small molecule drugs
and biopharmaceuticals. Due to their unique mirror image
configuration Spiegelmers® are not metabolized and do not hybridize
with native nucleic acids. Unlike conventional nucleic acids,
Spiegelmers® do not activate the innate immune response via toll-like
receptors and they showed an exceptionally favorable immunogenicity
profile in pre-clinical testing.

About NOXXON Berlin-based NOXXON Pharma AG is a clinical stage
biotechnology company focusing on the development of Spiegelmers® for
the treatment of inflammatory diseases and hematological indications.
NOXXON is in possession of a broad patent estate and has access to a
readily scalable GMP production. In addition to its in-house
programs, NOXXON discovers and develops Spiegelmers® in collaboration
with partners from the pharmaceutical industry, including Lilly,
Hoffmann La-Roche, and Pfizer. The business strategy of NOXXON is to
broaden this range of collaborations through co-development and
licensing agreements for the proprietary clinical and pre-clinical
products as well as technology-based multi-target partnerships.
Currently the company has two compounds in clinical development. The
declared goal of NOXXON is to establish its oligonucleotide-based
drug discovery platform (Spiegelmers®) as the leading 'scaffold'
technology to create new chemical entities with superior properties.
NOXXON´s investors are TVM Capital, Sofinnova Partners, Edmond de
Rothschild Investment Partners, Deutsche Effecten- und
Wechsel-Beteiligungsgesellschaft (DEWB), Seventure Partners, Dow
Venture Capital, Dieckell Group, FCP OP MEDICAL BioHealth-Trends, IBG
Risikokapitalfonds, VC Fonds Berlin, and others.

Website: http://www.noxxon.com

General contact:
Emmanuelle Delabre
NOXXON Pharma AG
Max-Dohrn-Strasse 8-10
10589 Berlin, Germany
Phone: + 49-30-726247-100
FAX: + 49-30-726247-225
Email: edelabre@noxxon.com

end of announcement euro adhoc
--------------------------------------------------------------------------------

ots Originaltext: Deutsche Effecten- und Wechsel-Beteiligungsges. AG (DEWB)
Im Internet recherchierbar: http://www.presseportal.de

Further inquiry note:

Marco Scheidler

Tel.: +49 (0) 3641 573-3600

E-Mail: marco.scheidler@dewb-vc.com

Branche: Financial & Business Services
ISIN: DE0008041005
WKN: 804100
Index: CDAX, Classic All Share, Prime All Share
Börsen: Frankfurt / regulated dealing/prime standard
Berlin / free trade
Stuttgart / free trade
München / free trade